Riboxx Pharma collaborates with CNBG to evaluate potential of Riboxxim TLR3 agonist
As part of the research collaboration, Riboxx will provide access to Riboxxim to enable CNBG to perform an evaluation, in conjunction with CNBG’s antigen, against the disease target.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.